There has been a large amount of speculation concerning the differences in the outcomes in patients who have gastric cancer in the Eastern and Western worlds. The differences in biology, surgical and adjuvant treatment have been used to explain such differences. There are clear differences observed in the histology (diffuse vs. intestinal), tumor location (proximal vs. distal), environmental exposures, dietary factors and Helicobacter pylori status. A higher incidence of gastric cancer in the East has led to screening programs, and leading to an earlier stage at presentation. Surgical treatment differs in that the extended lymph node dissection is routinely practiced in the Asian countries. Additionally, different adjuvant therapeutic regimens are used in both regions. The purpose of this review is to describe the differences in both presentation and treatment between the East and the West.
Introduction
Although the incidence of gastric cancer has been declining in most industrialized nations over the past two decades, it still remains the second leading cause of cancer related deaths worldwide. node dissection is routinely practiced in Asian countries, leading to greater lymph node retrieval. Whether this leads to stage migration or to a direct therapeutic effect has yet to be resolved. Laparoscopic gastrectomy has also been much more widely adopted in the East compared to the West. Furthermore, adjuvant therapy differs between the two regions.
The purpose of this review is to describe the differences in both presentation and treatment between the East and the West. We will highlight the differences in clinicopathological presentation, discuss the differences in both surgical and adjuvant treatment, and discuss the differences in survival outcomes.
Stage Differences
The incidence of gastric cancer is higher in Eastern countries compared to the West. This has led to the adoption of mass cancer screening programs in countries like Japan. (8) In Japan, annual screening with a double-contrast barium technique and endoscopy is recommended for persons over the age of 40 years. As such, many series have shown that gastric cancer tends to present with earlier staged lesions than their Western counterparts.(10,11) Based on reports from cancer registries, 53% of gastric cancers in Japan were localized when diagnosed, as opposed to 27% of those in the United States (US). This has been touted as a potential reason for the discrepancy in survival, although several series have demonstrated differences in survival when stratified by stage. (12, 13) Additionally, there may be some variation in pathologic evaluation between the US and Japan. (9, 14, 15) Japanese pathologists rely heavily on nuclear cytologic and glandular architecture abnormalities, whereas Western pathologists require the presence of invasion to diagnose carcinoma. Therefore, it may be that patients in Japan may have less advanced tumors than US patients even within Tstage.
Biology
One major difference between Eastern and Western gastric cancer is the location of the tumor. Western countries have a much higher incidence of tumors located in the proximal third of the stomach. (10) (11) (12) (16) (17) (18) In fact, the incidence of proximal gastric cancer has been increasing steadily in the US, even while the incidence of gastric cancer is on the decline. (19, 20) Proximal tumors are known to be associated with worse outcomes and could explain the differences between the two regions. who were treated at 13 institutions throughout Korea. The local recurrence rate was 6%, however there were no gastric cancer related deaths in these recurrences.
The use of EMR has been widely adopted in the East. It is estimated that approximately 50% of Stage IA gastric cancer is treated by EMR in Japan. Indications for EMR include well to moderately differentiated tumors that are confined to the mucosa. Superficially elevated tumors must be less than 2 cm and those that are flat or depressed should be less than 1 cm. There should be no ulceration or scar present and there should be no lymphatic or venous involvement. (27) Unlike Japan, EMR has not been as widely adopted in Western countries; however its use is starting to increase.
Lymph node dissection
The surgical approach to lymph node dissection has differed between the East and the West. D2 lymphadenectomy, which entails systematic dissection of the perigastric nodes along with the nodes along the celiac artery and its branches, is the standard of care in Japan and Eastern countries. In Western countries, D1 lymph node dissection (perigastric nodes only) is routinely performed. Lymph node dissection in the West has been driven by two large European randomized controlled trials which compared D1 to D2 lymphadenectomy (Table 1) . Cuschieri et al. (28, 29) reported the results of a multi-center randomized controlled trial from the United Kingdom (UK). In it, 400 patients were randomized to either D1 or D2 lymphadenectomy. The results showed a significantly higher morbidity (46% vs. 28%, P＜0.001) and mortality (13% vs. 6.5%, P=0.04) in the D2 arm. This was mainly driven by distal pancreatectomy and splenectomy.(28) There was no difference seen in overall survival or disease-specific survival between D1 and D2 lymph node dissection. (29) This study was highly criticized due to contamination and non-compliance. The median number of lymph nodes retrieved was 17 in the D2 group and 13 for the D1.
Additionally, many Eastern surgeons find the mortality rate unacceptably high. The second major European study was the Dutch Gastric Cancer trial, in which 711 patients were randomized to either D2 or D1 lymph node dissection. All surgeons were instructed by an expert from Japan and all D2 lymph node dissections were supervised by a specially trained surgeon. Despite this there was still non-compliance in 36% of D1 and 51% of D2 dissections. There remains no significant difference in overall survival. However, there is improved loco-regional control in the D2 arm and there is improved gastric cancer mortality in the D2 arm (37% vs.
48%, P=0.01).(32)
Whether the 15 year results will influence treatment patterns in the US remains to be seen.
In the East, the standard of care is a D2 lymph node dissection. Many Japanese surgeons consider the results of the Dutch and UK trials to have an unacceptably high mortality rate and poor survival rates. Peri-operative mortality in the Japan Clinical Oncology Group (JCOG) 9501 trial was 0.8% and the 5 year survival was 70%,(33) whereas in the European trials mortality was 4~6% and 5-year survival 33~35% (7, 34) . Trials in the East have focused on more extensive lymph node dissections than D2. There has been one randomized trial out of Taiwan which compared D1 and D3 lymphadenectomy. In it, 221 patients were randomized at a single institution, in which 3 highly trained surgeons performed all the operations. In their hands, the morbidity rate was higher in the D3 group (17.1% vs. 7.3%, P=0.012) however there was no operative mortality reported in either group. 
Differences in Adjuvant Therapy
Approaches to multi-modality therapy differ between the East and West. Approaches in the West have been driven by two randomized controlled trials that showed a benefit to adjuvant therapy ( Table 2 The main criticism is the surgical quality of control in these trials.
In the INT 0116 trial only 10% of patients had a D2 lymphadenectomy. In fact, 54% of the patients had a D0 lymphadenectomy.
Similarly, in the MAGIC trial, only 41% of patients had a D2 
Conclusions
There exist clear differences in the both the surgical and adjuvant treatments as well as the long term outcomes in the treatment of gastric cancer between the East and the West. Eastern surgeons perform more radical lymph node dissections, while the practice in the West is driven by the negative results both the UK and Dutch trials. Whether the 15 year results of the Dutch trial will change practices remains to be seen. Western physicians either focus on peri-operative chemotherapy or adjuvant chemoradiotherapy, while those in the East use adjuvant S1.
